mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
-0.064 |
0.05 |
mRNA |
CCT036477 |
CTRPv2 |
pan-cancer |
AAC |
-0.068 |
0.05 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.066 |
0.06 |
mRNA |
OSI-930 |
CTRPv2 |
pan-cancer |
AAC |
-0.072 |
0.06 |
mRNA |
fingolimod |
CTRPv2 |
pan-cancer |
AAC |
-0.071 |
0.06 |
mRNA |
erismodegib |
CTRPv2 |
pan-cancer |
AAC |
-0.075 |
0.06 |
mRNA |
Bortezomib |
gCSI |
pan-cancer |
AAC |
0.13 |
0.06 |
mRNA |
Gemcitabine |
CTRPv2 |
pan-cancer |
AAC |
-0.066 |
0.06 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.064 |
0.06 |
mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.069 |
0.06 |